Former IQ news editor Jon Chapple fundraising for cancer care
Former IQ news editor Jon Chapple has launched a fundraising campaign for life-saving cancer treatment.
The 34-year-old writer and PR account manager was diagnosed with stage-four bowel cancer in January 2022, aged 32, and has since undergone radiotherapy, chemotherapy and surgery.
“While the combination of chemotherapy and surgery seemed to be successful, my cancer is aggressive and grew back in my liver within a couple of months of being off chemo,” Chapple wrote on his Go Fund Me page. “For this reason, I have now been told no further surgery is possible.”
He is now hoping to raise £75,000 for dendritic cell therapy (also known as cancer vaccines) in Germany – a treatment that is not available through the NHS.
“It’s a miracle treatment: one that could allow me to once again live a ‘normal’ life, able to participate in the things – and make the kind of plans for the future – you expect to be able to in your early 30s,” the post continues.
“It’s a miracle treatment: one that could allow me to once again live a ‘normal’ life”
“When I asked my doctor in the UK, he told me, frankly, that dendritic vaccines are the future of cancer care. Unfortunately, such personalised treatments are still decades away from being on the NHS.
“They are currently only available privately and only in Germany, and are way out of my price range: £50,000 is a conservative estimate for the consultations, the creation of the vaccines, and the vaccines themselves (initially four), and that’s only for the first round of jabs. Novel treatments like dendritic cell therapy, which has a success rate of 60% for stage-four cancers, are now my only hope of being cured – but it will take the kindness of strangers to help me be able to afford it.”
Chapple was IQ‘s news editor for nearly six years, between 2016 and 2021. He recently wrote a comment piece on his journey since leaving for pastures new and his experience with stage-four bowel cancer.
Donate to Jon Chapple’s fundraising page here.
Get more stories like this in your inbox by signing up for IQ Index, IQ’s free email digest of essential live music industry news.